Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy

Cancer Biology and Therapy

Volumn 16, Issue 5, 2015, Pages 662-670

  Wyluda, Edward J ^a   Cheng, Jihua ^a   Schell, Todd D ^a   Haley, Jeremy S ^a   Mallon, Carol ^a   Neves, Rogerio I ^a   Robertson, Gavin ^a   Sivik, Jeffrey ^a   Mackley, Heath ^a   Talamo, Giampaolo ^a   Drabick, Joseph J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

BRAF inhibitor; Cytotoxic therapy; Immunotherapy; Interleukin 2; Ipilimumab; Metastatic melanoma; Treatment of melanoma

Indexed keywords

ANTINUCLEAR ANTIBODY; B RAF KINASE; CELECOXIB; HYDROCORTISONE; INTERLEUKIN 2; IPILIMUMAB; LACTATE DEHYDROGENASE; LEVOTHYROXINE; STEROID; TEMOZOLOMIDE; TRAMETINIB; VEMURAFENIB; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADRENAL METASTASIS; ADULT; ARTHRITIS; ARTICLE; AXILLARY LYMPH NODE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CEREBROVASCULAR ACCIDENT; CHILL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; IN-TRANSIT METASTASIS; INGUINAL LYMPH NODE; INGUINAL REGION; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; PARESIS; POLYARTHRITIS; SPLEEN METASTASIS; STEROID THERAPY; SUBSTITUTION THERAPY; SYNOVITIS; T LYMPHOCYTE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VITILIGO; WIDE EXCISION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84943758836     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1026507     Document Type: Article

References (50)

1. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14: 5610-8; PMID: 18765555; http://dx. doi. org/10. 1158/1078-0432. CCR-08-0116.
2. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-16; PMID: 10561265.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23; PMID: 20525992; http://dx. doi. org/10. 1056/NEJMoa1003466.
4. Chow S, Cove-Smith L, Schmitt M, Hawkins R. Highdose interleukin 2-induced myocarditis: can myocardial damage reversibility be assessed by cardiac MRI? J Immunother 2014; 37: 304-8; PMID: 24810642; http://dx. doi. org/10. 1097/CJI. 0000000000000036.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19; PMID: 20818844; http://dx. doi. org/10. 1056/NEJMoa1002011.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16; PMID: 21639808; http://dx. doi. org/10. 1056/NEJMoa1103782.
7. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-66; PMID: 10623706.
8. Kottschade LA, Suman VJ, Amatruda T. 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011; 117: 1704-10; PMID: 21472717; http://dx. doi. org/10. 1002/cncr. 25659.
9. National Comprehensive Cancer Network: Melanoma (Version 3. 2014). http://www. nccn. org/professionals/physi cian_gls/pdf/melanoma. pdf. Accessed April 19, 2014.
10. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26; PMID: 21639810; http://dx. doi. org/10. 1056/NEJMoa1104621.
11. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. New Eng J Med 2013; 368: 1365-6; PMID: 23550685; http://dx. doi. org/10. 1056/NEJMc1302338.
12. Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biol Ther 2010; 10: 1091-7; PMID: 20930514; http://dx. doi. org/10. 4161/cbt. 10. 11. 13452.
13. High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma": NCT 01124734. (Accessed at http://clinical trials. gov/ct2/show/NCT01124734.).
14. Hiniker SM, Chen DS, Reddy S, Chang DT, Jones JC, Mollick JA, Swetter SM, Knox SJ. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 2012; 5: 404-7; PMID: 23323154; http://dx. doi. org/10. 1593/tlo. 12280.
15. Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 2014; 88: 986-97; PMID: 24661650; http://dx. doi. org/10. 1016/j. ijrobp. 2013. 08. 035.
16. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart D. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-5; PMID: 23302800; http://dx. doi. org/10. 1038/nature11814.
17. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4C CD25(hi) Foxp3C regulatory T cells in cancer patients. Blood 2006; 107: 2409-14; PMID: 16304057; http://dx. doi. org/10. 1182/blood-2005-06-2399.
18. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4CCD25C regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169-77; PMID: 16505437; http://dx. doi. org/10. 1200/JCO. 2005. 03. 6830.
19. Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, et al. Interleukin-2 administration alters the CD4CFOXP3C T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67: 7487-94; PMID: 17671219; http://dx. doi. org/10. 1158/0008-5472. CAN-07-0565.
20. Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer Treat Rev 2013; 39: 879-85; PMID: 23725878; http://dx. doi. org/10. 1016/j. ctrv. 2013. 04. 006.
21. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. Highdose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 Suppl 1: S11-4; PMID: 10685652.
22. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009; 23: 488-96; PMID: 19544689.
23. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-17; PMID: 25034862; http://dx. doi. org/10. 1016/S0140-6736(14)60958-2.
24. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33; PMID: 23724867; http://dx. doi. org/10. 1056/NEJMoa1302369.
25. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54; PMID: 22658127; http://dx. doi. org/10. 1056/NEJMoa1200690.
26. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014; 32: 2248-54; PMID: 24958825; http://dx. doi. org/10. 1200/JCO. 2013. 52. 1377.
27. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237-51; PMID: 22437869; http://dx. doi. org/10. 1038/nrc3237.
28. Homet B, Ribas A. New drug targets in metastatic melanoma. J Pathol 2014; 232: 134-41; PMID: 24027077; http://dx. doi. org/10. 1002/path. 4259.
29. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14; PMID: 22356324; http://dx. doi. org/10. 1056/NEJMoa1112302.
30. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65; PMID: 22735384; http://dx. doi. org/10. 1016/S0140-6736(12)60868-X.
31. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-88; PMID: 25265492; http://dx. doi. org/10. 1056/NEJMoa1406037.
32. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, et al. Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. J Clin Oncol 2014; 32: 3697-704; PMID: 25287827; http://dx. doi. org/10. 1200/JCO. 2014. 57. 3535.
33. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-14; PMID: 22663011; http://dx. doi. org/10. 1056/NEJMoa1203421.
34. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20; PMID: 19934295; http://dx. doi. org/10. 1158/1078-0432. CCR-09-1624.
35. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63: 4490-6; PMID: 12907622.
36. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120: 1111-24; PMID: 20234093; http://dx. doi. org/10. 1172/JCI40269.
37. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72; PMID: 23157435; http://dx. doi. org/10. 1146/annurev-immunol-032712-100008.
38. Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 2011; 9: 196; PMID: 22077981; http://dx. doi. org/10. 1186/1479-5876-9-196.
39. Vieweg J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007; 13: 727s-32s; PMID: 17255301; http://dx. doi. org/10. 1158/1078-0432. CCR-06-1924.
40. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restifo NP, Zanovello P. Identification of a CD11b(C)/Gr-1(C)/CD31(C) myeloid progenitor capable of activating or suppressing CD8(C) T cells. Blood 2000; 96: 3838-46; PMID: 11090068.
41. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010; 16: 6040-8; PMID: 21169256; http://dx. doi. org/10. 1158/1078-0432. CCR-10-1911.
42. Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res 2014; 74: 3205-17; PMID: 24736544; http://dx. doi. org/10. 1158/0008-5472. CAN-13-3461.
43. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, Flaherty KT, Lawrence DP, Fisher DE, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70: 5213-9; PMID: 20551059; http://dx. doi. org/10. 1158/0008-5472. CAN-10-0118.
44. Disis ML, Bernhard H, Jaffee EM. Use of tumourresponsive T cells as cancer treatment. Lancet 2009; 373: 673-83; PMID: 19231634; http://dx. doi. org/10. 1016/S0140-6736(09)60404-9.
45. Appay V. The physiological role of cytotoxic CD4(C) T-cells: the holy grail? Clin Exp Immunol 2004; 138: 10-3; PMID: 15373899; http://dx. doi. org/10. 1111/j. 1365-2249. 2004. 02605. x.
46. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18: 2039-47; PMID: 22271879; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1823.
47. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med 2009; 7: 102; PMID: 19948067; http://dx. doi. org/10. 1186/1479-5876-7-102.
48. Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, et al. FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation. Clin Cancer Res 2014; 20: 4994-5000; PMID: 25096067; http://dx. doi. org/10. 1158/1078-0432. CCR-14-0776.
49. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(C) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-50; PMID: 20156971; http://dx. doi. org/10. 1084/jem. 20091918.
50. Kaufman HL, Wolchok JD. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 2006; 24: 2230-2; PMID: 16710020; http://dx. doi. org/10. 1200/JCO. 2006. 05. 6952.